摘要
BACKGROUND： The effectiveness of gene therapy is closely related to the efficiency of vector transfection and expression. OBJECTIVE： This study was designed to transfect a human brain glioma cell line with recombinant Vaccinia virus expressing the interleukin-2 （rVV-IL-2） gene, and to observe IL-2 expression and glioma cell proliferation potential after transfection. DESIGN： Experimental observation. SETTING： Department of Neurosurgery, Shenyang Military Area Command of Chinese PLA. MATERIALS： The rVV-IL-2 vectors were obtained through homologous recombination and screening in the Second Military Medical University of Chinese PLA. The human brain glioma cell line and IL-2-dependent cells were produced by the Second Military Medical University of Chinese PLA. Human IL-2 was produced by Genzyme Corporation. METHODS： At passage day l, Veto cells were amplified l ; 1 for virus and cells. A human brain glioma cell line was transfected using amplified Vaccinia viral vectors at varying multiplicities of infection （MOI）. At 2, 4, 6, 8, 12, and 24 hours post-transfection, superuatant was collected to determine by MTT assay IL-2 expression levels in IL-2 dependent cells. The transfected and non-transfected cells were divided into 4 groups, namely MOI1 ： 1, MOI 5 ： 1, MOI 10 ： 1, and control groups. MAIN OUTCOME MEASURES： IL-2 expression at different time points after transfection of human brain glioma cells with varying MOI of Vaccinia viral vectors; in vitro proliferation capacity of human brain glioma cells among the 4 groups. RESULTS： IL-2 expression was detectable 4 hours after Vaccinia viral vector transfection and reached 300 kU/L by 8 hours. There was no significant difference in the proliferating rate of human brain glioma cells among the 4 groups （P 〉 0.05）. CONCLUSION： Vaccinia viral vectors can transfect human brain glioma cells in vitro and express high levels of IL-2. Vaccinia virus and high IL-2 expression do not influence the proliferation rate of human brain glioma cells in vitro.
BACKGROUND： The effectiveness of gene therapy is closely related to the efficiency of vector transfection and expression. OBJECTIVE： This study was designed to transfect a human brain glioma cell line with recombinant Vaccinia virus expressing the interleukin-2 （rVV-IL-2） gene, and to observe IL-2 expression and glioma cell proliferation potential after transfection. DESIGN： Experimental observation. SETTING： Department of Neurosurgery, Shenyang Military Area Command of Chinese PLA. MATERIALS： The rVV-IL-2 vectors were obtained through homologous recombination and screening in the Second Military Medical University of Chinese PLA. The human brain glioma cell line and IL-2-dependent cells were produced by the Second Military Medical University of Chinese PLA. Human IL-2 was produced by Genzyme Corporation. METHODS： At passage day l, Veto cells were amplified l ; 1 for virus and cells. A human brain glioma cell line was transfected using amplified Vaccinia viral vectors at varying multiplicities of infection （MOI）. At 2, 4, 6, 8, 12, and 24 hours post-transfection, superuatant was collected to determine by MTT assay IL-2 expression levels in IL-2 dependent cells. The transfected and non-transfected cells were divided into 4 groups, namely MOI1 ： 1, MOI 5 ： 1, MOI 10 ： 1, and control groups. MAIN OUTCOME MEASURES： IL-2 expression at different time points after transfection of human brain glioma cells with varying MOI of Vaccinia viral vectors; in vitro proliferation capacity of human brain glioma cells among the 4 groups. RESULTS： IL-2 expression was detectable 4 hours after Vaccinia viral vector transfection and reached 300 kU/L by 8 hours. There was no significant difference in the proliferating rate of human brain glioma cells among the 4 groups （P 〉 0.05）. CONCLUSION： Vaccinia viral vectors can transfect human brain glioma cells in vitro and express high levels of IL-2. Vaccinia virus and high IL-2 expression do not influence the proliferation rate of human brain glioma cells in vitro.
